Validation of a method evaluating T cell metabolic potential in compliance with ICH Q2 (R1).

ABSTRACT:

Background

Metabolic cell features are able to give reliable information on cell functional state. Thus, metabolic potential assessment of T cells in malignancy setting represents a promising area, especially in adoptive cell therapy procedures. Easy to set up and convenient Seahorse technology have recently been proposed by Agilent Technologies and it could be used to monitor T cells metabolic potential. However, this method demonstrates an inter-assay variability and lacks practices standardization.

Results

We aimed to overcome these shortcomings thanks to a lymphoblastic derived JURKAT cell line seeding in each experiment to standardize the Seahorse process. We used an adapted XF Cell MitoStress Kit protocol, consisting in the evaluation of basal, stressed and maximal gly

SUBMITTER: Mercier-Letondal P 

PROVIDER: S-EPMC7789274 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature